Intuitive Surgical is in a sustained downtrend, with the stock declining 24.1% over the past year compared to the S&P 500's gain of 20.9%. The current price of $388.97 sits just 2.8% above its 52-week low of $378.50 and 35.6% below the 52-week high of $603.88, indicating the stock is near the bottom of its range. This positioning suggests a deeply oversold condition, but also reflects persistent selling pressure and a lack of bullish conviction. Short-term momentum remains negative: the stock has fallen 6.6% in the past month and 15.1% in the past three months, underperforming the S&P 500 by 7.2% and 21.4%, respectively. The 1-month decline of 6.6% is accelerating relative to the 3-month decline, signaling intensifying bearish momentum. The 1-year downtrend is intact, and the recent price action shows no signs of a reversal, with the stock making lower lows in July 2026. Key support lies at the 52-week low of $378.50; a break below this level would likely trigger further selling and target the next major support zone near $350. Resistance is at the 52-week high of $603.88, but nearer-term resistance is around $420–$430, the June 2026 highs. The stock's beta of 1.46 indicates it is 46% more volatile than the market, meaning larger swings in both directions, which amplifies risk for position sizing. A breakout above $430 would suggest a potential trend reversal, while a breakdown below $378.50 would confirm a continuation of the downtrend.

Intuitive Surgical's revenue trajectory is strong and accelerating. In Q1 2026, revenue reached $2.771 billion, up 22.96% year-over-year, compared to 21.5% growth in Q4 2025 and 18.8% in Q3 2025. The growth is driven by all three segments: Instruments and Accessories ($1.686 billion), Services ($434 million), and Systems ($651 million), with Systems revenue benefiting from increased da Vinci placements. This accelerating top-line growth supports the investment case for a company with a dominant market position and expanding total addressable market. Profitability is robust and improving. Net income in Q1 2026 was $821.5 million, up from $698.4 million in Q1 2025, representing a net margin of 29.6%. Gross margin remained stable at 66.1%, while operating margin expanded to 30.9% from 25.7% a year ago, reflecting operating leverage. The company is highly profitable with a net income of $821.5 million and a trailing twelve-month free cash flow of $2.834 billion. The balance sheet is fortress-like: debt-to-equity is a mere 0.017, and the current ratio is 4.87, indicating ample liquidity. Free cash flow generation is strong, with $808.6 million in Q1 2026 alone, easily covering capital expenditures of $103.3 million. ROE stands at 16.0%, reflecting efficient capital use. The company has no dividend, instead reinvesting cash into growth and share repurchases ($1.12 billion in Q1 2026).